阿德福韦酯治疗拉米夫丁耐药的慢性乙型肝炎的疗效观察

Clinical research of Lamivudine resistance patients of chronic hepatitis B treated with Adefovior

目的:探讨阿德福韦酯治疗拉米夫定耐药的乙型肝炎的临床疗效。方法:选择本院2008年4月～2010年3月收治的乙型肝炎患者中对拉米夫定耐药者120例,随机分为研究组(60例)和对照组(60例),研究组在拉米夫定的基础上给予阿德福韦酯治疗,对照组继续给予拉米夫定治疗,治疗1年后观察治疗效果。结果:研究组治疗总有效率明显高于对照组,两组比较差异有统计学意义(χ2=16.73,P<0.05),两组治疗前谷丙转氨酶(ALT)、总胆红素(TBIL)差异无统计学意义(t=0.83、0.62,P>0.05),治疗后研究组ALT、TBIL明显低于对照组,两组比较差异有统计学意义(t=12.68、5.12,P<0.05)。治疗过程中两组不良反应事件发生率比较,差异无统计学意义(χ2=1.26,P>0.05),不良反应较轻,均未出现因不良反应停药患者。结论:乙型肝炎出现拉米夫定耐药后,给予阿德福韦酯治疗,效果较好,值得应用。

Objective： To investigate clinical effect of Adefovior in treatment of Lamivudine resistant patients with hepatitis B.Methods： 120 cases of Lamivudine resistant patients with hepatitis B in our hospital from April 2008 to March 2010 were divided into research group（60 csaes） and control group（60 cases）,patients in research group were given Adefovior treatment on the basis of Lamivudine,control group continued Lamivudine treatment,to observe treatment effect after 1 year.Results： The total effective rate of research group was higher than control group after treatment,the difference was statistically significant（χ2=16.73,P〈0.05）,There are no significant difference of ALT,TBIL in two groups before treatment（t=0.83,0.62,P〉0.05）,but ALT,TBIL of research group was significantly lower than control group after treatment,the difference was statistically significant（t=12.68,5.12,P〈0.05）.The incidence of adverse events in two groups during the treatment was no significant（χ2=1.26,P〉0.05）,adverse reactions were mild and no patient discontinued treatment.Conclusion： Clinical effect of Adefovior in treatment of Lamivudine resistant patients is good and it is worthy of application.